MRI Data Suggest Simufilam is Not Associated with
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD...
Source: globenewswire.com
Withdrawal Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Withdrawal Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Withdrawal Study Today - Breaking & Trending Today
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
Transferred anti-IL 18 monoclonal antibody product to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK... | August 4, 2022
Source: marketscreener.com
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies
GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its
Source: miragenews.com
Myovant Sciences and Pfizer Present Data on Relugolix
BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the...
Source: globenewswire.com
Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript
Operator Good day, everyone, and welcome to Myovant Sciences first-quarter of fiscal year 2021 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Ryan Crowe, vice president of investor relations at Myovant. Please go ahead. Ryan Crowe -- Vice President of Investor Relations Thank you, operator. Good morning and thanks for joining us today to review the financial results of Myovant's first quarter of fiscal year 2021 and to discuss other corporate and business updates. Joining me for today's call are Dave Marek, Myovant's chief execut...
Source: fool.com